Importantly, despite the high prevalence of TP53 mutations in t-MDS, they did not affect transplant outcome, even if more studies are needed, focused on the heterogeneity of TP53-mutated t-MDS to identify which cases could require novel emerging treatments [113]. This evidence concerns the gene TP53 and myelodysplastic syndrome.